Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Preliminary efficacy and safety of fruquintinib as maintenance therapy after first-line treatment in metastatic colorectal cancer (mCRC): A multicenter, randomized, open-label clinical trial (the FRONT study).
Authors
Xiaojing Xu
Department of Oncology, Cancer center, Zhongshan Hospital, Fudan University, Shanghai, China
Xiaojing Xu , Yiyi Yu , Qing Liu , Yan Wang , Yuehong Cui , Wei Li , Qian Li , Yi Feng , Li Liang , Shan Yu , Minzhi Lv , Tianshu Liu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04296019
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 126)
DOI
10.1200/JCO.2024.42.3_suppl.126
Abstract #
126
Poster Bd #
H11
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of fruquintinib plus mFOLFOX6/FOLFIRI as first-line therapy in advanced metastatic colorectal cancer (mCRC).
First Author: Fuxiang Zhou
Poster
2024 ASCO Annual Meeting
Fruquintinib plus capecitabine versus capecitabine as first-line maintenance treatment of metastatic colorectal cancer (mCRC): Update results from the randomized, controlled, phase Ib/II study.
First Author: Wenhua Li
Poster
2023 ASCO Annual Meeting
An open-label, multicenter, adaptive, phase Ib/II study of QL1706 or QL1604 plus bevacizumab as first-line treatment in patients with advanced hepatocellular carcinoma.
First Author: Feng Bi
Poster
2022 ASCO Annual Meeting
Biweekly mXELIRI versus FOLFIRI in combination with bevacizumab as the first-line treatment for metastatic colorectal cancer (EXIST): A multicenter, randomized, open-label, phase 2 study.
First Author: Zhichao Jiang